Compare Stocks: HCA, GSK, ZTS, and BSX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BSX Boston Scientific	$45.60 +1.2%	$45.84	$41.38 ▼ $105.65	$65.29B	0.58	16.30 million shs	16.01 million shs
GSK GSK	$50.60 +2.3%	$49.55	$42.85 ▼ $61.69	$100.04B	0.33	5.66 million shs	5.60 million shs
HCA HCA Healthcare	$465.15 +2.3%	$428.29	$353.99 ▼ $556.52	$98.48B	1.1	1.12 million shs	1.32 million shs
ZTS Zoetis	$80.01 +0.5%	$74.23	$68.77 ▼ $148.30	$32.89B	0.74	4.16 million shs	3.74 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BSX Boston Scientific	+1.38%	+5.23%	+5.04%	+6.02%	-54.66%
GSK GSK	+2.35%	+9.43%	+0.89%	-0.33%	+14.72%
HCA HCA Healthcare	+2.11%	+1.03%	+8.74%	+24.85%	+7.38%
ZTS Zoetis	+0.43%	+7.67%	+11.86%	+7.88%	-44.86%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BSX Boston Scientific	$45.60 +1.2%	$45.84	$41.38 ▼ $105.65	$65.29B	0.58	16.30 million shs	16.01 million shs
GSK GSK	$50.60 +2.3%	$49.55	$42.85 ▼ $61.69	$100.04B	0.33	5.66 million shs	5.60 million shs
HCA HCA Healthcare	$465.15 +2.3%	$428.29	$353.99 ▼ $556.52	$98.48B	1.1	1.12 million shs	1.32 million shs
ZTS Zoetis	$80.01 +0.5%	$74.23	$68.77 ▼ $148.30	$32.89B	0.74	4.16 million shs	3.74 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BSX Boston Scientific	+1.38%	+5.23%	+5.04%	+6.02%	-54.66%
GSK GSK	+2.35%	+9.43%	+0.89%	-0.33%	+14.72%
HCA HCA Healthcare	+2.11%	+1.03%	+8.74%	+24.85%	+7.38%
ZTS Zoetis	+0.43%	+7.67%	+11.86%	+7.88%	-44.86%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BSX Boston Scientific	2.81	Moderate Buy	$68.23	49.64% Upside
GSK GSK	2.05	Hold	$55.33	9.36% Upside
HCA HCA Healthcare	2.63	Moderate Buy	$467.61	0.53% Upside
ZTS Zoetis	2.25	Hold	$98.07	22.56% Upside

Current Analyst Ratings Breakdown

Latest HCA, GSK, ZTS, and BSX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/20/2026	BSX Boston Scientific	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/20/2026	ZTS Zoetis	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy ➝ Hold	$103.00 ➝ $83.00
10/16/2026	ZTS Zoetis	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy ➝ Neutral	$74.00
10/16/2026	ZTS Zoetis	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy ➝ Neutral	$74.00
10/14/2026	BSX Boston Scientific	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$57.00 ➝ $51.00
10/13/2026	BSX Boston Scientific	Mizuho Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$55.00
10/12/2026	HCA HCA Healthcare	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$431.00 ➝ $460.00
10/9/2026	BSX Boston Scientific	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target		$60.00 ➝ $55.00
10/9/2026	GSK GSK	Wolfe Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform	$70.00
10/8/2026	HCA HCA Healthcare	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C+) ➝ Buy (B-)
10/7/2026	BSX Boston Scientific	Evercore Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$65.00 ➝ $52.00

(Data available from 10/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BSX Boston Scientific	$21.00B	3.15	$4.09 per share	11.16	$16.49 per share	2.77
GSK GSK	$33.20B	3.08	$6.14 per share	8.24	$10.32 per share	4.90
HCA HCA Healthcare	$75.60B	1.33	$46.24 per share	10.06	($12.14) per share	-38.32
ZTS Zoetis	$9.47B	3.49	$7.61 per share	10.52	$7.56 per share	10.58

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BSX Boston Scientific	$2.90B	$2.47	18.46	13.57	1.09	17.50%	19.28%	10.89%	10/28/2026 (Estimated)
GSK GSK	$7.54B	$3.20	15.82	10.12	2.23	14.56%	43.23%	11.60%	10/28/2026 (Estimated)
HCA HCA Healthcare	$6.78B	$29.87	15.31	14.51	1.53	8.77%	-244.79%	11.10%	10/27/2026 (Estimated)
ZTS Zoetis	$2.67B	$6.07	12.10	12.66	1.18	27.49%	74.89%	18.59%	11/5/2026 (Estimated)

Latest HCA, GSK, ZTS, and BSX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	ZTS Zoetis	$1.51	N/A	N/A	N/A	$2.30 billion	N/A
10/28/2026	Q3 2026	BSX Boston Scientific	$0.7460	N/A	N/A	N/A	$5.10 billion	N/A
10/28/2026	Q3 2026	GSK GSK	$1.33	N/A	N/A	N/A	$11.74 billion	N/A
10/27/2026	Q3 2026	HCA HCA Healthcare	$6.66	N/A	N/A	N/A	$19.33 billion	N/A
8/6/2026	Q2 2026	ZTS Zoetis	$1.85	$1.87	+$0.02	$1.65	$2.50 billion	$2.47 billion
7/29/2026	Q2 2026	BSX Boston Scientific	$0.83	$0.86	+$0.03	$0.61	$5.38 billion	$5.44 billion
7/28/2026	Q2 2026 & Strategy update	GSK GSK	$1.27	$1.36	+$0.09	$0.28	$11.02 billion	$11.14 billion
7/24/2026	Q2 2026	HCA HCA Healthcare	$7.56	$7.59	+$0.03	$7.62	$19.76 billion	$20.23 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BSX Boston Scientific	N/A	N/A	N/A	N/A	N/A
GSK GSK	$1.77	3.50%	-7.86%	55.31%	N/A
HCA HCA Healthcare	$3.12	0.67%	+30.19%	10.45%	6 Years
ZTS Zoetis	$2.12	2.65%	+20.11%	34.93%	14 Years

Latest HCA, GSK, ZTS, and BSX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
10/8/2026	ZTS Zoetis	quarterly	$0.53	2.9%	10/30/2026	10/30/2026	12/1/2026
7/28/2026	GSK GSK	quarterly	$0.4515	3.65%	8/14/2026	8/14/2026	10/8/2026
7/23/2026	HCA HCA Healthcare	quarterly	$0.78	0.72%	9/16/2026	9/16/2026	9/30/2026
1/1/2100	GSK GSK	quarterly	$0.4206	4.3%	8/15/2025	8/15/2025	10/9/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BSX Boston Scientific	0.43	1.24	0.74
GSK GSK	0.81	0.82	0.52
HCA HCA Healthcare	N/A	0.99	0.90
ZTS Zoetis	2.87	3.08	1.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BSX Boston Scientific	89.07%
GSK GSK	15.74%
HCA HCA Healthcare	62.73%
ZTS Zoetis	92.80%

Insider Ownership

Company	Insider Ownership
BSX Boston Scientific	0.34%
GSK GSK	10.00%
HCA HCA Healthcare	1.50%
ZTS Zoetis	0.22%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BSX Boston Scientific	59,000	1.45 billion	1.44 billion	Optionable
GSK GSK	66,841	2.02 billion	1.82 billion	Optionable
HCA HCA Healthcare	320,000	216.50 million	213.25 million	Optionable
ZTS Zoetis	14,500	413.22 million	412.32 million	Optionable

HCA, GSK, ZTS, and BSX Headlines

Recent News About These Companies

Zoetis: Weakening Fundamentals Overshadow The Discount

October 20 at 5:30 PM | seekingalpha.com

Zoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment

October 20 at 4:42 PM | businesswire.com

Jefferies cuts target to USD 83 for Zoetis stock

October 20 at 8:36 AM | ad-hoc-news.deA

Zoetis (NYSE:ZTS) Research Coverage Started at The Goldman Sachs Group

October 19 at 1:18 AM | americanbankingnews.com

Zoetis (NYSE:ZTS) Stock Rating Raised to "Hold" at The Goldman Sachs Group

October 17, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Phibro Animal Health (PAHC) and Zoetis (ZTS)

October 17, 2026 | theglobeandmail.com

Zoetis’ Valuation Has Fallen Sharply, but Has the Market Overreacted?

October 16, 2026 | insidermonkey.com

3 Reasons ZTS is Risky and 1 Stock to Buy Instead

October 15, 2026 | finance.yahoo.com

Zoetis (ZTS) Hit by Guidance Cuts, Met with Market Shrug

October 15, 2026 | finance.yahoo.com

Zoetis Inc. stock underperforms Wednesday when compared to competitors despite daily gains

October 14, 2026 | marketwatch.com

Zoetis (ZTS) Board Update And Dividend Keep Undervalued Narrative In Focus

October 14, 2026 | finance.yahoo.com

Zoetis (NYSE:ZTS) Stock Purchased by Rep. Gilbert Ray Cisneros, Jr.

October 14, 2026 | marketbeat.com

Branded Pharmaceuticals Stocks Q2 In Review: Zoetis (NYSE:ZTS) Vs Peers

October 13, 2026 | finance.yahoo.com

Zoetis Appoints Iris Knobloch to Board of Directors

October 13, 2026 | tipranks.com

Zoetis Appoints Iris Knobloch to its Board of Directors

October 13, 2026 | businesswire.com

Zoetis (ZTS) Stock May Trade At A Discount As Q2 Pressure Persists

October 11, 2026 | finance.yahoo.com

Zoetis (ZTS) Outpaces Stock Market Gains: What You Should Know

October 9, 2026 | zacks.com

Zoetis Inc. (NYSE:ZTS) Plans Quarterly Dividend of $0.53

October 9, 2026 | marketbeat.com

Zoetis (ZTS) Declares $0.53 Quarterly Dividend; 2.9% Yield

October 8, 2026 | streetinsider.com

Zoetis (ZTS) Says Study Shows Simparica Trio Outperformed A Rival On Resistant Heartworm

October 8, 2026 | finance.yahoo.com

Zoetis Declares Fourth-Quarter Dividend, Signals Ongoing Strength

October 8, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

HCA, GSK, ZTS, and BSX Company Descriptions

Boston Scientific NYSE:BSX

$45.60 +0.55 (+1.21%)

Closing price 10/20/2026 03:59 PM Eastern

Extended Trading

$45.28 -0.31 (-0.68%)

As of 10/20/2026 07:56 PM Eastern

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

GSK NYSE:GSK

$50.60 +1.14 (+2.30%)

Closing price 10/20/2026 03:59 PM Eastern

Extended Trading

$50.76 +0.16 (+0.32%)

As of 10/20/2026 07:50 PM Eastern

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

HCA Healthcare NYSE:HCA

$465.15 +10.27 (+2.26%)

Closing price 10/20/2026 03:59 PM Eastern

Extended Trading

$465.40 +0.25 (+0.05%)

As of 10/20/2026 07:57 PM Eastern

HCA Healthcare, Inc., through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. The company also operates outpatient health care facilities consisting of freestanding ambulatory surgery centers, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, rehabilitation and physical therapy centers, radiation and oncology therapy centers, physician practices, and various other facilities. In addition, it operates behavioral hospitals, which provide therapeutic programs comprising child, adolescent and adult psychiatric care, adolescent and adult alcohol, drug abuse treatment, and counseling services. The company was formerly known as HCA Holdings, Inc. HCA Healthcare, Inc. was founded in 1968 and is headquartered in Nashville, Tennessee.

Zoetis NYSE:ZTS

$80.01 +0.42 (+0.53%)

Closing price 10/20/2026 03:59 PM Eastern

Extended Trading

$80.00 -0.02 (-0.02%)

As of 10/20/2026 08:00 PM Eastern

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HCA, GSK, ZTS, and BSX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HCA, GSK, ZTS, and BSX Earnings

Compare Dividends

Latest HCA, GSK, ZTS, and BSX Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HCA, GSK, ZTS, and BSX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HCA, GSK, ZTS, and BSX Company Descriptions

Boston Scientific NYSE:BSX

GSK NYSE:GSK

HCA Healthcare NYSE:HCA

Zoetis NYSE:ZTS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools